Novo Nordisk gives shelved Parkinson’s therapy to Zuckerberg-backed firm
▼ Summary
– Novo Nordisk has transferred its experimental stem-cell therapy for Parkinson’s disease, STEM-PD, to the AI biotech startup Cellular Intelligence.
– Novo will take an equity stake in Cellular Intelligence and is eligible for future milestone payments and royalties.
– Cellular Intelligence plans to use its AI platform to advance the STEM-PD treatment, which Novo discontinued in October.
Novo Nordisk has licensed an experimental Parkinson’s therapy to a startup backed by a Mark Zuckerberg-linked venture, marking a strategic pivot for a treatment the Danish pharma giant shelved last year. Under the deal, Novo will acquire an equity stake in Cellular Intelligence and is eligible for future milestone payments and royalties tied to the program’s progress.
The therapy in question, known as STEM-PD, is a stem-cell-derived treatment originally developed by Novo for Parkinson’s disease. The company discontinued its internal development of STEM-PD in October 2024. Now, Cellular Intelligence plans to resurrect the candidate by applying its proprietary AI platform to the therapy, aiming to accelerate its path toward clinical testing and potential approval.
Cellular Intelligence operates at the intersection of artificial intelligence and regenerative medicine. The startup’s technology is designed to analyze complex biological data, optimize cell therapy manufacturing, and predict patient responses. By layering these computational tools onto STEM-PD, the company hopes to overcome the scientific and logistical hurdles that led Novo to halt the program.
The financial structure of the agreement gives Novo a direct stake in the startup’s future success while offloading the development risk. For Cellular Intelligence, the deal provides access to a validated clinical asset and Novo’s institutional expertise, without the burden of building a Parkinson’s pipeline from scratch.
This transaction reflects a broader trend in biotech: large pharmaceutical companies increasingly hand off shelved assets to agile startups equipped with advanced AI tools. Rather than letting promising science languish, these partnerships allow for a second chance at development, often with faster timelines and lower costs.
STEM-PD is a cell replacement therapy designed to restore dopamine-producing neurons in the brain, a key pathological feature of Parkinson’s. If the AI-enhanced approach succeeds, it could reopen a treatment avenue that many had written off. For now, all eyes are on Cellular Intelligence to see whether its algorithms can breathe new life into a dormant therapy.
(Source: The Next Web)
